Stockscreener 앱 받기
3.695
2.77%
0.155
전일 마감가:
$3.54
열려 있는:
$3.54
하루 거래량:
289.67K
Relative Volume:
0.28
시가총액:
$458.33M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-1.2525
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
-4.27%
1개월 성능:
+3.94%
6개월 성능:
+25.88%
1년 성능:
+120.48%
1일 변동 폭
$3.50
$3.705
1주일 범위
$3.25
$3.84
52주 변동 폭
$1.05
$4.80
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.6999 | 438.52M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.12 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.41 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.95 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.86 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
Will ADC Therapeutics SA benefit from sector rotation2025 Market Overview & Long-Term Investment Growth Plans - mfd.ru
Moving Averages: Why is ADC Therapeutics SA stock going upStock Surge & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Risk Off: Is ADC Therapeutics SA stock showing strong momentumPortfolio Gains Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Weekly Trades: Can ADC Therapeutics SA continue delivering strong returnsLayoff News & Verified Entry Point Detection - mfd.ru
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - marketscreener.com
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13% - Intellectia AI
Breakouts Watch: Will ADC Therapeutics SA benefit from sector rotationWeekly Stock Report & Growth Oriented Trade Recommendations - baoquankhu1.vn
Insider Trends: Can ADC Therapeutics SA disrupt its industryQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Is ADC Therapeutics SA stock attractive for retirement portfoliosWeekly Gains Report & Real-Time Volume Surge Alerts - bollywoodhelpline.com
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 47.2% - MarketBeat
ADCT: Zynlonta's pivotal trials aim to transform its market reach and drive major growth from 2027 - TradingView
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - sharewise.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - Chartmill
Bull Bear: Why ADC Therapeutics SA stock could benefit from AI revolution2025 Risk Factors & Weekly High Momentum Picks - Bộ Nội Vụ
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ADC Therapeutics posts preliminary 2025 revenue of about $73M - MSN
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy - TipRanks
How geopolitical tensions affect ADC Therapeutics SA stock2025 Sector Review & Technical Buy Zone Confirmations - Улправда
Can ADC Therapeutics SA Common Shares stock sustain margin levelsCEO Change & Low Drawdown Trading Techniques - ulpravda.ru
Is ADC Therapeutics SA Common Shares stock testing key supportQuarterly Market Review & Free High Accuracy Swing Entry Alerts - Улправда
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook - The Globe and Mail
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Sahm
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Ye - GuruFocus
Can ADC Therapeutics SA stock rebound after recent weakness2025 Winners & Losers & Free Reliable Trade Execution Plans - Улправда
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates - PR Newswire
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
ADC Therapeutics SA Common Shares (NY: ADCT - markets.financialcontent.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC ... - Bluefield Daily Telegraph
Will ADC Therapeutics SA stock outperform international peers2026 world cup usa national team round of 32 top scorers high defensive line tactical prediction guide - ulpravda.ru
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
ADC Therapeutics Announces New Employee Inducement Grant - 富途牛牛
New employee at ADC Therapeutics gets 4-year stock option package - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Graphic Packaging Holding Company - GlobeNewswire Inc.
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why - Yahoo Finance
Is ADC Therapeutics SA a good long term investmentOptions Trading Strategies & Free Take Advantage Of Momentum - earlytimes.in
Corient Private Wealth LLC Makes New Investment in ADC Therapeutics SA $ADCT - MarketBeat
Risk Report: Will ADC Therapeutics SA stock beat EPS estimatesQuarterly Profit Report & Fast Gaining Stock Reports - Улправда
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - marketscreener.com
Is ADC Therapeutics SA stock a contrarian buyJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
ADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Will ADC Therapeutics SA stock beat EPS estimatesMarket Activity Report & Safe Entry Zone Identification - Улправда
Wall Street Recap: Is ADC Therapeutics SA Common Shares stock undervalued historically2025 EndofYear Setup & Weekly High Return Forecasts - Улправда
How buybacks impact ADC Therapeutics SA stock value2025 Investor Takeaways & Entry and Exit Point Strategies - Улправда
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
0.55%
자본화:
|
볼륨(24시간):